Author

F. Bayrakdar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. B. Altas· 1 shared A. Yilmazer· 1 shared C. Z. Ketre Kolukirik· 1 shared G. G. Ozgumus· 1 shared G. Korukluoglu· 1 shared G. Y. Summak· 1 shared H. Nazir· 1 shared K. C. Akcali· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. B. Altas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2

M. A. Unal, O. Besbinar, H. Nazir, G. Y. Summak, F. Bayrakdar, L. G. Delogu, T. Taskin, S. A. Ozkan, K. C. Akcali, A. Yilmazer

This study compares the antiviral effects of favipiravir, umifenovir, and camostat mesylate against SARS-CoV-2 using in silico and in vitro methods, finding that combination treatments are more effective than single drugs.

bioRxiv · Jan 11, 2022 · PreprintPharmacology & Toxicology

40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations

G. Korukluoglu, M. Kolukirik, F. Bayrakdar, G. G. Ozgumus, A. B. Altas, Y. Cosgun, C. Z. Ketre Kolukirik

The paper develops a 40-minute RT-qPCR assay to rapidly screen for SARS-CoV-2 Spike N501Y and HV69-70del mutations with 100% agreement with sequencing results.

bioRxiv · Jan 26, 2021 · PreprintMicrobiology